Cadrenal Therapeutics, Inc. Common Stock
CVKD
$0.98
Change (1 day)
$32.55
Year High
$5.40
Year Low
Categories
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
